Mending walls by Petsko, Gregory A
Before I built a wall I’d ask to know  
What I was walling in or walling out
Robert Frost, ‘Mending Wall’
In rural New England, as in much of the rest of the world, 
people  mark  their  territory,  like  some  race  of 
architecturally-adept spaniels, by building a wall around 
its  borders.  In  some  cases  this  is  done  for  defensive 
purposes. In others, it is meant to keep in something that 
should  not  be  allowed  to  roam  freely  (spaniels  again, 
perhaps). But much of the time it is simply there to say, 
‘this is mine, not yours.’
Walls aren’t inherently bad things, but in his classic 
poem  on  the  subject,  Robert  Frost  wonders  if  they 
might not have unintended consequences. Build a wall 
to  keep  something  unpleasant  out,  and  you  are  also 
walling  yourself  in,  possibly  with  something  else 
unpleasant. The point is that walls discourage human 
interaction,  prevent  the  mixing  of  ideas,  and  create 
inbred - often xenophobic - cultures.
There  is  much  talk  today  about  the  importance  of 
interdisciplinary research, and much bemoaning of how 
difficult it is to carry it out, especially when the aim is to 
bridge the gap between basic discovery and translation to 
the  clinic.  One  often  hears  the  word  ‘silos’  used  to 
describe  the  separateness  of  the  cultures.  Silos  is  an 
evocative  word,  conjuring  images  of  isolated  white 
cylinders against the flat horizon of a Midwestern farm 
state; but I prefer to talk in terms of walls. Silos seem 
inherently separate. Walls can be knocked down.
Nowhere  is  the  need  for  demolition  more  apparent 
than in the way biomedical research is conducted. There 
are  19  separate  institutes  at  the  National  Institutes  of 
Health  (NIH),  the  largest  financial  supporter  of 
biomedical research in the world. They are, for the most 
part, named for distinct diseases or organ systems (The 
National  Cancer  Institute;  The  National  Eye  Institute; 
The  National  Institute  of  Diabetes  and  Digestive  and 
Kidney  Disease;  The  National  Heart,  Lung  and  Blood 
Institute, and so on). They fund research in their own 
mission  areas,  and  seldom  venture  outside  the  walls 
created  by  their  specific  name  and  charter,  or  their 
physical  walls  -  they  are  generally  housed  in  separate 
buildings  on  the  sprawling  NIH  campus.  Biomedical 
research funding reflects this separation: if you wish to 
apply for support for a cancer research project, you send 
your application to the National Cancer Institute, not to 
the National Institute on Aging, even though the risk for 
most  cancers  increases  markedly  with  age.  There  are 
instances where multiple institutes and centers may come 
together to fund a project, but often they don’t have the 
opportunity  to  do  so,  because  the  separateness  of 
different areas of biomedical research is ingrained in the 
minds of the applicants, who target their proposals - and 
their investigations - accordingly.
And who would expect them to do otherwise? Go to 
any academic medical center in the US, or abroad, and 
you will find distinct departments of oncology for cancer 
research  and  treatment,  rheumatology  or  immunology 
for  arthritis  and  autoimmune  diseases,  neurology  for 
Alzheimer’s disease, psychiatry for schizophrenia, and so 
on - mirroring the disease - and organ-centeredness of 
the way we train medical specialists. Such divisions may 
make some sense in clinical care (though I wouldn’t mind 
discussing that sometime), but increasingly, as we come 
to understand the cellular and molecular basis of disease, 
they  make  no  sense  in  terms  of  research,  basic  or 
translational.
Parkinson’s disease research is typically carried out in 
neurology departments. One would never expect to find 
Parkinson’s researchers in departments of pediatrics or 
other  places  where  inborn  errors  of  metabolism  are 
studied,  and  yet  the  biggest  genetic  risk  factor  for  the 
development of Parkinson’s disease is to be a carrier for 
the rare, autosomal recessive, lysosmal storage disorder 
called Gaucher disease. So tight is the connection that 
one expects virtually all Gaucher patients, who have two 
mutated  copies  of  the  relevant  gene,  to  develop 
Parkinson’s disease if they live long enough. The risk for 
the carriers, who have a single mutant copy, is almost ten 
times that of normal age-matched controls. Understanding 
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lead  to  novel  approaches  to  Parkinson’s  therapy  (for 
example, could a drug to treat Gaucher disease reduce 
the risk of Parkinson’s disease in Gaucher carriers down 
to normal levels?), but to do so will require smashing the 
wall between the very different medical disciplines that 
study and treat these seemingly different diseases.
Or consider the connections between obesity, diabetes, 
and cancer. Obesity frequently leads to type II diabetes, 
which makes sense in terms of the pathways that connect 
metabolism with insulin resistance. But diabetics also are 
at  greatly  increased  risk  for  many  forms  of  cancer  -  a 
connection  that  is  much  harder  to  explain  (although 
some  recent  studies  that  revive  the  old  idea  of  the 
Warburg  effect  and  its  importance  for  cancer  cell 
metabolism may offer a partial explanation).
Lest you think that, at least, is starting to become clear, 
you might want to think again. Because if you examine the 
connection between diseases - what clinicians refer to as 
comorbidity - you run into paradoxes that cry out for more 
research.  Obesity  and  diabetes  are  positively  correlated 
with increased cancer risk? Not if you have schizophrenia.
Schizophrenics, in addition to myriad other problems, 
tend  to  have  very  unhealthy  lifestyles.  They  are  often 
chain smokers, and have high incidence of obesity and 
obesity-related diabetes. What they don’t have is cancer. 
Cancer  rates  in  schizophrenics  are  significantly  lower 
than  they  should  be  given  the  positive  comorbidity 
between cancer and obesity/diabetes in those who do not 
suffer from this mental illness. This inverse comorbidity 
even extends to lung cancer, which ought to be extremely 
high among schizophrenics given their dependence on 
cigarettes, and yet isn’t.
I could list dozens more examples. (A favorite of mine 
is the inverse comorbidity between Parkinson’s disease 
and  nearly  all  cancers  -  with  the  striking  exception  of 
melanoma,  which  is  so  common  among  Parkinson’s 
patients that neurologists have started to look for it. And 
if  you’re  wondering  whether  the  inverse  is  true,  that 
melanoma  survivors  are  at  greatly  elevated  risk  for 
Parkinson’s,  but  that  those  who  have  had  most  other 
forms of cancer are at lower than normal Parkinson’s risk, 
the answer is, that is indeed the case.) Every one of these 
connections offers a fascinating and, I think, fertile field 
for research. Yet such research is strikingly rare.
Balkanization  of  biomedical  research  funding  by 
disease  phenotype  and  organ  system  is  one  reason 
comprehensive  studies  of  the  connections  between 
diseases are hard to find. Send a Parkinson’s-melanoma 
grant to the National Institute of Neurologic Disorders 
and Stroke, and you are likely to find it sent back with a 
puzzled,  ‘Shouldn’t  this  go  to  the  National  Cancer 
Institute?’ Which, I suspect, would be equally puzzled by 
this grant that clearly is about neurologic diseases. But 
even if the funding agencies are more open-minded than 
that (and I suspect some of them might be), it’s hard to 
imagine people trained in clinical research investigating 
such  topics  in  the  first  place,  because  their  training  is 
very much disease-focused, and their research tends to 
be as well.
I believe we need a new way of thinking about disease. 
We  have  to  get  away  from  the  classical  emphasis  on 
tissue,  organ,  and  phenotypic  presentation  and  think 
more about pathways and processes within the cell and 
organism. Seen this way, cancer is a disease of aberrant 
cell survival and Alzheimer’s is a disease of aberrant cell 
death - should they not be inversely correlated? In fact, 
they  are.  Alzheimer’s  patients  are  at  much  higher  risk 
relative to age-matched controls for developing Parkinson’s 
disease - could the two disorders be intimately connected 
at the molecular level? There is increasing evidence that 
they are. It’s difficult and expensive to do clinical trials on 
Parkinson’s  disease  but  much  easier  to  do  trials  on 
Gaucher disease - once we realize they are connected, the 
rare  disease  may  offer  a  route  to  the  treatment  of  the 
more common one. More than half of all schizophrenic 
patients  are  not  helped  by  the  currently  available 
treatment - perhaps we should look at some of the path-
ways that are involved in cancers for new targets and ideas.
Of course, none of this can happen without a change in 
the way biomedical research is organized and researchers 
are trained. There may be good reason from a clinical 
perspective to have separate departments of neurology 
and oncology, but given what I’ve told you, shouldn’t they 
be in the same building, and shouldn’t they have some 
joint seminars and grand rounds? Shouldn’t the National 
Institutes of Health develop more mechanisms for cross-
disease  research  funding?  That  would  be  a  worthy 
objective for NIH’s new National Center for Advancing 
Translational  Sciences.  And  shouldn’t  NIH  (and  its 
foreign counterparts) also develop specific mechanisms 
to promote cross-disciplinary training? Not just for basic 
researchers,  where  the  idea  is  already  fashionable,  but 
especially for physician-scientists. The biggest barrier to 
working  across  fields  is  the  differences  in  jargon  and 
mindset that each has. Overcoming that barrier is a job 
for education.
Translating discoveries from the concept to the clinic is 
hard, and it’s getting harder as we tackle more chronic, 
non-infectious  diseases  (although  the  possibility  that 
many of them may actually have an infectious etiology is 
something  that  bears  remembering,  and  suggests  yet 
another  need  for  breaking  down  the  walls  between 
disciplines).  We  can’t  leave  any  stone  unturned  in  our 
quest to improve human health, and some of the biggest 
unturned  stones  exist  because  we  have  built  walls  of 
specialization, paradigms, and tradition around the fields 
we work in.
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observation:
Something there is that doesn’t love a wall,  
That wants it down.
When it comes to biomedical research, I think I know 
what that something is. It’s called progress.
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